France Sets Precedent With Off-Label Avastin Move
This article was originally published in Scrip
Executive Summary
True to its word, the French health ministry has announced that Roche's anticancer Avastin (bevacizumab) will be reimbursed for the off-label treatment of wet AMD as of Sept. 1, 2015. In doing so, the ministry is setting a precedent by encouraging the use of a drug for an unapproved indication for purely financial reasons.